ZYME Q4 2021 Earnings — Zymeworks Inc. Revenue & Financial Results | Market Cap Arena

ZYMEZymeworks Inc.

$2B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M+26.7% YoY

Gross Profit

-$35M-175.2% margin

Operating Income

-$41M-205.6% margin

Net Income

-$39M-197.0% margin

EPS (Diluted)

$-0.75

QoQ Revenue Growth

+352.1%

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$55M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$389M

Total Liabilities

$140M

Stockholders' Equity

$249M

Cash & Equivalents

$202M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$16M	+26.7%
Gross Profit	-$35M	-$24M	-44.5%
Operating Income	-$41M	-$38M	-8.8%
Net Income	-$39M	-$38M	-3.3%

Revenue Segments

Upfront Fee

$18M73%

License and Service

$6M22%

Milestone Payment

$1M4%